FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136257905> ?p ?o ?g. }

• W3136257905 endingPage "466.e34" @default.
• W3136257905 startingPage "466.e17" @default.
• W3136257905 abstract "Objectives To investigate the noninferiority of intensive voice therapy and compare its effects with weekly voice therapy on multidimensional outcomes of voice and well-being, satisfaction, and attendance in people with muscle tension dysphonia (MTD). The study further aimed to explore clinician's perceptions of barriers and enablers to implementation of intensive therapy. Study Design Noninferiority randomised controlled trial with nested focus group. Methods Twenty adults with MTD were randomised to receive either weekly voice therapy (1 hour per week for 8 weeks) or intensive voice therapy (1 hour, 4 days per week for 2 weeks). Participants were assessed by a blinded assessor twice before treatment, once post treatment and once at 4 weeks follow up on the primary outcome measure VHI and a range of secondary auditory-perceptual, acoustic, and patient (i.e., VoiSS, satisfaction) and clinician reported outcome measures (i.e., AusTOMs, attendance rates). Five Speech Language Pathologists also participated in a focus group to explore barriers and enablers to implementing intensive therapy, with questions and analyses guided by the Theoretical Domains Framework. Results While noninferiority for the primary outcome measure VHI was not confirmed, secondary outcome measures revealed comparable within group clinically important improvements for VoiSS and the AusTOMs, as well as selected acoustic and auditory-perceptual measures for both groups. A trend of more improvements being maintained in the intensive group was identified. Comparably high satisfaction and attendance was also found between groups. Clinicians reported more enablers than barriers to providing intensive therapy which included beliefs that it led to greater progression and consolidation of patient learning, was supported by the local context and was associated with positive emotions. Barriers related to difficulties with booking and scheduling and the belief that intensive therapy was not for all patients. Conclusions While the current study was likely underpowered to establish non-inferiority of intensive therapy, secondary outcomes suggested that intensive therapy may produce comparable benefits to voice, wellbeing, satisfaction and attendance compared to weekly therapy and may be a viable therapy option for individuals with MTD. When implementing intensive therapy, clinicians should consider patient's preferences and availability, as well as systems which allow for flexible booking and therapy provision for patients. Clear recommendations for future research including the use of a larger sample and telehealth are also provided. To investigate the noninferiority of intensive voice therapy and compare its effects with weekly voice therapy on multidimensional outcomes of voice and well-being, satisfaction, and attendance in people with muscle tension dysphonia (MTD). The study further aimed to explore clinician's perceptions of barriers and enablers to implementation of intensive therapy. Noninferiority randomised controlled trial with nested focus group. Twenty adults with MTD were randomised to receive either weekly voice therapy (1 hour per week for 8 weeks) or intensive voice therapy (1 hour, 4 days per week for 2 weeks). Participants were assessed by a blinded assessor twice before treatment, once post treatment and once at 4 weeks follow up on the primary outcome measure VHI and a range of secondary auditory-perceptual, acoustic, and patient (i.e., VoiSS, satisfaction) and clinician reported outcome measures (i.e., AusTOMs, attendance rates). Five Speech Language Pathologists also participated in a focus group to explore barriers and enablers to implementing intensive therapy, with questions and analyses guided by the Theoretical Domains Framework. While noninferiority for the primary outcome measure VHI was not confirmed, secondary outcome measures revealed comparable within group clinically important improvements for VoiSS and the AusTOMs, as well as selected acoustic and auditory-perceptual measures for both groups. A trend of more improvements being maintained in the intensive group was identified. Comparably high satisfaction and attendance was also found between groups. Clinicians reported more enablers than barriers to providing intensive therapy which included beliefs that it led to greater progression and consolidation of patient learning, was supported by the local context and was associated with positive emotions. Barriers related to difficulties with booking and scheduling and the belief that intensive therapy was not for all patients. While the current study was likely underpowered to establish non-inferiority of intensive therapy, secondary outcomes suggested that intensive therapy may produce comparable benefits to voice, wellbeing, satisfaction and attendance compared to weekly therapy and may be a viable therapy option for individuals with MTD. When implementing intensive therapy, clinicians should consider patient's preferences and availability, as well as systems which allow for flexible booking and therapy provision for patients. Clear recommendations for future research including the use of a larger sample and telehealth are also provided." @default.
• W3136257905 created "2021-03-29" @default.
• W3136257905 creator A5001590183 @default.
• W3136257905 creator A5006256949 @default.
• W3136257905 creator A5011037751 @default.
• W3136257905 creator A5017613171 @default.
• W3136257905 creator A5024999044 @default.
• W3136257905 creator A5026099067 @default.
• W3136257905 creator A5074879209 @default.
• W3136257905 creator A5079764061 @default.
• W3136257905 creator A5080672561 @default.
• W3136257905 creator A5082405502 @default.
• W3136257905 creator A5085052866 @default.
• W3136257905 date "2023-05-01" @default.
• W3136257905 modified "2023-10-14" @default.
• W3136257905 title "Effectiveness of Intensive Voice Therapy Versus Weekly Therapy for Muscle Tension Dysphonia: A Noninferiority Randomised Controlled Trial With Nested Focus Group" @default.
• W3136257905 cites W1578384183 @default.
• W3136257905 cites W1900154594 @default.
• W3136257905 cites W1977953045 @default.
• W3136257905 cites W1979650467 @default.
• W3136257905 cites W1983752151 @default.
• W3136257905 cites W1983968959 @default.
• W3136257905 cites W1988670509 @default.
• W3136257905 cites W1994997260 @default.
• W3136257905 cites W1995516199 @default.
• W3136257905 cites W2003042698 @default.
• W3136257905 cites W2012616066 @default.
• W3136257905 cites W2016100576 @default.
• W3136257905 cites W2017055811 @default.
• W3136257905 cites W2018908598 @default.
• W3136257905 cites W2026896477 @default.
• W3136257905 cites W2026950754 @default.
• W3136257905 cites W2033531571 @default.
• W3136257905 cites W2039304985 @default.
• W3136257905 cites W2046932018 @default.
• W3136257905 cites W2047392794 @default.
• W3136257905 cites W2051964202 @default.
• W3136257905 cites W2059037214 @default.
• W3136257905 cites W2059043759 @default.
• W3136257905 cites W2059872075 @default.
• W3136257905 cites W2077109464 @default.
• W3136257905 cites W2077273488 @default.
• W3136257905 cites W2081914181 @default.
• W3136257905 cites W2086266554 @default.
• W3136257905 cites W2091260974 @default.
• W3136257905 cites W2100598867 @default.
• W3136257905 cites W2111877017 @default.
• W3136257905 cites W2145555293 @default.
• W3136257905 cites W2146591442 @default.
• W3136257905 cites W2152740900 @default.
• W3136257905 cites W2158401855 @default.
• W3136257905 cites W2163161389 @default.
• W3136257905 cites W2168668537 @default.
• W3136257905 cites W2170658821 @default.
• W3136257905 cites W2184760858 @default.
• W3136257905 cites W2208801704 @default.
• W3136257905 cites W2293040502 @default.
• W3136257905 cites W2346483403 @default.
• W3136257905 cites W2539050349 @default.
• W3136257905 cites W2547252084 @default.
• W3136257905 cites W2585484989 @default.
• W3136257905 cites W2674995983 @default.
• W3136257905 cites W2761736394 @default.
• W3136257905 cites W2771665324 @default.
• W3136257905 cites W2773490640 @default.
• W3136257905 cites W2789854861 @default.
• W3136257905 cites W2887505065 @default.
• W3136257905 cites W2891117141 @default.
• W3136257905 cites W2922853138 @default.
• W3136257905 cites W2936210391 @default.
• W3136257905 cites W2948945992 @default.
• W3136257905 cites W2969670848 @default.
• W3136257905 cites W2973515423 @default.
• W3136257905 cites W3006772124 @default.
• W3136257905 cites W3009825501 @default.
• W3136257905 cites W3017498114 @default.
• W3136257905 cites W3046870694 @default.
• W3136257905 doi "https://doi.org/10.1016/j.jvoice.2021.02.011" @default.
• W3136257905 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33741236" @default.
• W3136257905 hasPublicationYear "2023" @default.
• W3136257905 type Work @default.
• W3136257905 sameAs 3136257905 @default.
• W3136257905 citedByCount "6" @default.
• W3136257905 countsByYear W31362579052021 @default.
• W3136257905 countsByYear W31362579052022 @default.
• W3136257905 countsByYear W31362579052023 @default.
• W3136257905 crossrefType "journal-article" @default.
• W3136257905 hasAuthorship W3136257905A5001590183 @default.
• W3136257905 hasAuthorship W3136257905A5006256949 @default.
• W3136257905 hasAuthorship W3136257905A5011037751 @default.
• W3136257905 hasAuthorship W3136257905A5017613171 @default.
• W3136257905 hasAuthorship W3136257905A5024999044 @default.
• W3136257905 hasAuthorship W3136257905A5026099067 @default.
• W3136257905 hasAuthorship W3136257905A5074879209 @default.
• W3136257905 hasAuthorship W3136257905A5079764061 @default.
• W3136257905 hasAuthorship W3136257905A5080672561 @default.
• W3136257905 hasAuthorship W3136257905A5082405502 @default.
• W3136257905 hasAuthorship W3136257905A5085052866 @default.

• next